LAURUSLABS

Laurus Labs has reported a stellar Q1 FY27 performance

Laurus Labs has reported a stellar Q1 FY27 performance with net profit more than doubling to ₹368 crore, driven by strong growth in its CDMO (Contract Development and Manufacturing Organization) business and improved margins. The company’s stock hit new highs, reflecting investor confidence in its expansion plans and portfolio transformation. 📊 Key Financial Highlights (Q1 FY27) Net Profit: ₹368 crore, up 126% YoY (vs ₹163 crore last year). Revenue: ₹2,026 crore, up 29% YoY (vs ₹1,570 crore). EBITDA: ₹644 crore, up 66–67% YoY. EBITDA Margin: Expanded to 31.5–31.8% (from ~24.3% last year). Gross Margin: Improved to 62.7% (up ~330 basis points). 📈 Business Segment Performance CDMO Business: Revenue surged 67% YoY to ₹870 crore. Small molecules CDMO grew 69% YoY to ₹835 crore. Growth driven by late-stage clinical projects and commercial API supplies. Affordable Medicines (Generics): Revenue at ₹1,156 crore, up 10% YoY. Supported by steady ARV (antiretroviral) sales and volume growth. Sequential decline of 5% vs March quarter due to supply chain challenges. Bio (Large Molecules): Revenue grew 21% YoY to ₹35 crore. 🚀 Strategic Developments R&D Investments: ₹118 crore in Q1, up 74% YoY, focused on advanced biologics (gene therapy, antibody-drug conjugates). In-licensing Deals: Two Antibody Drug Conjugates (ADCs) from Aarvik Therapeutics for India markets. Expansion: Secured new land parcel in Visakhapatnam/Anakapalli for future manufacturing facilities. Global Presence: Opened office in South Africa to strengthen emerging market opportunities. 📊 Stock Market Impact Share Price: Rose to ~₹1,596–1,603 post-results, hitting a new all-time high. YTD Performance: Up 44–62% in 2026, significantly outperforming Nifty Pharma index. Investor Sentiment: Boosted by strong CDMO growth, margin expansion, and capex plans.